Advertisement

Current Treatment Options in Gastroenterology

, Volume 7, Issue 6, pp 501–508 | Cite as

Treatment of the pruritus of cholestasis

  • Nora V. Bergasa
Article

Opinion statement

The etiology of the pruritus of cholestasis is unknown. It is inferred that the pruritogen( s) is produced in the liver, excreted in bile, and as a result of cholestasis it accumulates in plasma. It may follow, logically, that the removal of the substance(s) that mediate pruritus leads to its resolution. The problem with this approach, however, is that the substance(s) is unknown; thus, it is not possible to reduce its serum levels specifically. Oral cholestyramine, a resin that is not absorbed, is associated with increased fecal excretion of certain substances, including cholesterol and bile acids. Many patients respond to treatment with cholestyramine with a relief of pruritus, which unfortunately may be temporary, but is well tolerated in general and it seems reasonable to prescribe it as an initial therapy. When pruritus is not relieved by resins, the use of opiate antagonists (eg, naloxone and naltrexone) is supported by data from controlled clinical trials. Butorphanol is an agonist at the kappa opioid receptor and an antagonist at the mu opioid receptor with minimal or absent abuse potential. The use of butorphanol spray in selective patients may be a therapeutic alternative. In uncontrolled observations dronabinol, an agonist at the cannabinoid B1 receptor, and sertraline, a serotonin reuptake inhibitor, have been reported to be associated with the relief of pruritus. The cannabinoidergic and serotoninergic systems participate in the mediation of nociception; therefore, there appears to be a rationale for the use of these drugs to treat pruritus. Data from controlled clinical trials on the use of dronabinol and sertraline, however, are not available at present.

Keywords

Opioid Receptor Primary Biliary Cirrhosis Cholestasis Naltrexone Main Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Bergasa NV: Pruritus in chronic liver disease: mechanisms and treatment. Curr Gastroenterol Rep 2004, 6: 10–16.PubMedCrossRefGoogle Scholar
  2. 2.
    Jinks SL, Carstens E: Superficial dorsal horn neurons identified by intracutaneous histamine: chemonociceptive responses and modulation by morphine. J Neurophysiol 2000, 84: 616–627.PubMedGoogle Scholar
  3. 3.
    Jones EA, Bergasa NV: The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990, 11: 884–887.PubMedCrossRefGoogle Scholar
  4. 4.
    Thornton JR, Losowsky MS: Opioid peptides and primary biliary cirrhosis. British Medical Journal 1988, 297: 1501–1504.PubMedCrossRefGoogle Scholar
  5. 5.
    Bergasa NV, Sabol SL, Young WS, et al.: Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995, 268: G346-G354.PubMedGoogle Scholar
  6. 6.
    Bergasa NV: Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002, 22: 107–113.PubMedCrossRefGoogle Scholar
  7. 7.
    Dagenais C, Ducharme J, Pollack GM: Uptake and efflux of the peptidic delta-opioid receptor agonist. Neurosci Lett 2001, 301: 155–158.PubMedCrossRefGoogle Scholar
  8. 8.
    Datta DV, Sherlock S: Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966, 50: 323–332.PubMedGoogle Scholar
  9. 9.
    Berg C: Use of colesevelam hydrochloride (Welchol) as a novel therapeutic agent for the management of refractory pruritus in chronic liver disease. Hepatology 2001, 34: 541.Google Scholar
  10. 10.
    Bergasa NV, Alling DW, Talbot TL, et al.: Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Annals of Internal Medicine 1995, 123: 161–167.PubMedGoogle Scholar
  11. 11.
    Wolfhagen FH, Sternieri E, Hop WC, et al.: Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997, 113: 1264–1269.PubMedCrossRefGoogle Scholar
  12. 12.
    Terg R, Coronel E, Sorsa J, et al.: Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis. J Hepatol 2002, 37: 717–722.PubMedCrossRefGoogle Scholar
  13. 13.
    Bachs L, Parés A, Elena M, et al.: Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992, 102: 2077–2080.PubMedGoogle Scholar
  14. 14.
    Mullally BA, Hansen WF: Intrahepatic cholestasis of pregnancy: review of the literature. Obstet Gynecol Surv 2002, 57: 47–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Ko MC, Lee H, Song MS, et al.: Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther 2003, 305: 173–179. The observation that the activation of kappa receptors prevented opiate-induced scratching in animals may facilitate the mechanism that underlies opiate-mediated pruritus and it may help create specific therapies.PubMedCrossRefGoogle Scholar
  16. 16.
    Richardson BP: Serotonin and nociception. Annals of the New York Academy of Science 1990, 600: 511–520.CrossRefGoogle Scholar
  17. 17.
    Schworer H, Hartmann H, Ramadori G: Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995, 61: 33–37.PubMedCrossRefGoogle Scholar
  18. 18.
    O’Donohue JW, Haigh C, Williams R: Ondansetron in the treatment of the pruritus of cholestasis: a randomised controlled trial. Gastroenterology 1997, 112: 1349.Google Scholar
  19. 19.
    Neff GW, O’Brien CB, Reddy KR, et al.: Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002, 97: 2117–2119.PubMedCrossRefGoogle Scholar
  20. 20.
    Gingold A, Bergasa NV: The cannabinoid agonist WIN 55, 212–2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sciences 2003, 73: 2741–2747.PubMedCrossRefGoogle Scholar
  21. 21.
    Ghent CN, Carruthers SG: Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988, 94: 488–493.PubMedGoogle Scholar
  22. 22.
    Emerick KM, Whitington PF: Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002, 35: 1501–1506.PubMedCrossRefGoogle Scholar
  23. 23.
    Ng VL, Ryckman FC, Porta G, et al.: Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2000, 30: 152–156.PubMedCrossRefGoogle Scholar
  24. 24.
    Stange J, Hassanein TI, Mehta R, et al.: The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002, 26: 103–110.PubMedCrossRefGoogle Scholar
  25. 25.
    Doria C, Mandala L, Smith J, et al.: Effect of molecular adsorbent recirculating system in hepatitis C virusrelated intractable pruritus. Liver Transpl 2003, 9: 437–443.PubMedCrossRefGoogle Scholar
  26. 26.
    Moore RY: Organization of the mammalian circadian system. In Circadian Clocks and Their Readjustments. Edited by Chadwick DJ, Ackrill K. London: John Wiley & Sons; 1993: 88–106.Google Scholar
  27. 27.
    Bergasa NV, Link MJ, Keogh M, et al.: Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001, 96: 1563–1570.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Nora V. Bergasa
    • 1
  1. 1.Division of HepatologyState University of New York, Downstate Medical CenterBrooklynUSA

Personalised recommendations